Navigation Links
Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
Date:3/31/2008

SHANGHAI, China, March 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech, the leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, was very honored to have Professor David W. C. MacMillan, a renowned researcher from Princeton University, as a WuXi PharmaTech Science Seminar Series speaker who delivered a lecture to the company's young scientists on March 25, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Aiming to keep the company's young scientists abreast of the latest drug R&D knowledge and technologies, the WuXi PharmaTech Science Seminar Series is a monthly program that invites accomplished researchers from academia and the industry to share their wealth of experience and expertise with the company's scientists.

Dr. David MacMillan obtained his undergraduate degree from Glasgow University, and in 1990 moved to the University of California, Irvine, where he obtained his Ph.D. under the direction of Larry E. Overman. Following postdoctoral research with David A. Evans at Harvard University, Dr. MacMillan began his independent research career at the University of California, Berkeley, in 1998. In 2000, he joined the department of chemistry at Caltech, and was promoted to full professor in 2003. He was appointed to the A. Barton Hepbum Chair of Chemistry and Director of the Merck Center for Catalysis at Princeton University in June 2006.

Dr. MacMillan is a leader in the currently active area of asymmetric organocatalysis. His numerous accomplishments have found widespread industrial application and his success is evidenced by the numerous awards and honors he has received from professional associations like the Royal Society of Chemistry, the American Chemical Society and the industry.

"We are very honored and privileged to have Dr. MacMillan as one of our seminar speakers. His remarkable achievements in the field of organic synthesis will motivate our young scientists," said Dr. Shuhui Chen, Chief Scientific Officer of the company. "As a research-driven company serving global pharmaceutical, biotechnology and medical device companies, we believe science has no boundary. We will continue inviting heavy-weight speakers to WuXi so that our scientists can learn from the best, and ultimately provide better services to our customers."

About WuXi PharmaTech

WuXi PharmaTech, headquartered in Shanghai, China, is a leading global pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the U.S. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies. Our services are designed to assist our global customers in shortening the time and lowering the cost of drug and medical device R&D by providing cost- effective and efficient outsourcing solutions. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Princeton scientists break choleras lines of communication
2. First look: Princeton researchers peek into deepest recesses of human brain
3. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
4. University of Iowa professor identifies new eating disorder
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
7. N.J. nurses are overworked according to Rutgers College of Nursing professor
8. Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award
9. Boston University School of Medicine Professor receives award from American Heart Association
10. Louisiana Tech professor is Small Times Innovator of the Year
11. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: